Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026

Abstract
“Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026” Report Highlights:

• Global Peptide Cancer Vaccine Market Trends Insight
• Global Peptide Cancer Drugs Market Opportunity: >USD 20 Billion
• Global Peptide Cancer Vaccine Clinical Trials Insight By Company, Indication & Phase
• Number Of Peptide Vaccines In Pipeline: >90
• Application of Peptide Cancer Vaccine Against Major Cancer

The developments of vaccines have shown incredible impact on human health system and have resulted in significant decrease in mortality rates from several diseases. Increase in prevalence of chronic disorders including cancer has urged the development of novel targeted therapeutics for their management. In recent times, researchers have exploited the use of vaccines to generate anti-tumor response in management of cancer.

The rapid approval of Provenge for the management of pancreatic cancer and the robust response in market has surged the development of more targeted vaccines in cancer. In recent times, peptides have emerged as a potential vaccine candidate owing to their small size, simple and cost efficient production and development process. Moreover, peptides are recognized to be highly specific and efficacious, safe and well tolerated. Given their attractive physical and chemical properties, researchers have developed several peptide based vaccines in management of wide range of cancers.

Currently, GV1001 (Riavaxtm, Tertomotide) is the only peptide based vaccine approved for the management of pancreatic cancer in Korea. , GV1001 is a 16-amino-acid peptide comprising a sequence from the human enzyme telomerase reverse transcriptase (TERT). Most cancers highly express TERT, and immunization with GV1001 aims to activate the immune system to recognize and kill cancer cells. The vaccine is currently under clinical trials and applications to gain approval in other countries.

Apart from this, a cocktail of peptide based cancer vaccines are present in preclinical and clinical studies and have shown encouraging response. Most of the drugs are present in the phase I and II clinical trials which suggests that the market will be flourished with several vaccines targeting different cancers in next 4-5 years. Moreover, in near future the market will see combination of vaccines along with other conventional drugs to improve their efficacy and specificity in targeting the complexity of cancer cells.

Keeping in mind the high adoption rates of the novel therapeutics in North America, it is expected that the region will dominate the global peptide cancer vaccine market for next few years. The high prevalence of cancer and the rising initiatives by government as well as private sectors will also propel the growth of peptide cancer vaccines in this area. In addition to this, Europe and Asia Pacific will also emerge as a potential market wing to high untapped opportunities, low cost of raw material, growing base of companies providing outsourcing services, flourishing biotech industry, and increasing investments in the R&D sector.

As per “Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026” report findings, it is estimated that the global peptide cancer vaccine will follow trajectory growth rates. The market will be favored by the advancement in science and arrival of novel technologies which will further enable the identification of potential targets in developing cancer vaccines. The arrival of peptide based cancer vaccine has caused prompting effects on the overall cancer therapy market and has helped it to make through all the challenges that have been on the way of becoming the most dominant market in the industry.

Content
1. Introduction to Peptide Cancer Vaccine

2. Need of Peptide Vaccines
2.1 Why Peptides – More Desirable
2.2 Peptide Vaccines V/S Traditional Vaccines

3. Classification of Peptide Vaccines
3.1 On the Basis of Sources Obtained
3.2 On the Basis of Length
3.3 On the Basis of Epitopes

4. Mechanism of Action of Peptide Cancer Vaccines
4.1 Immunological Cells Activated by Peptide Cancer Vaccines
4.2 Procedure of Synthetic Peptide Vaccine Development

5. Clinical Trials Efficacy Study of Synthetic Peptide Analog Obtained From WT1 Oncoprotein against Acute Myeloid Leukemia
5.1 Basic Layout of the Study
5.2 Introduction to WT1 Peptide
5.3 Methodologies Involved In the Clinical Study
5.4 Results of the Clinical Trial Study

6. Wide Spectrum Action of Peptide Cancer Vaccines Against Major Cancer
6.1 Colorectal Cancer
6.2 Lung Cancer
6.3 Pancreatic Cancer
6.4 Gastric Cancer
6.5 Prostate Cancer
6.6 Breast Cancer

7. Global Peptide Cancer Vaccine Market Overview

8. Global Peptide Cancer Vaccine Market Trends
8.1 Optimized Cryptic Peptides
8.2 Therapeutic CpG Peptide-Based Cancer Vaccine
8.3 Personalized Neoantigen Vaccination with Synthetic Long Peptides
8.4 Recombinant Peptide Vaccine
8.5 p53 Peptide-Pulsed Dendritic Cells Cancer Vaccines

9. Global Peptide Cancer Vaccine Pipeline Overview
9.1 By Country
9.2 By Company
9.3 By Patient Segment
9.4 By Phase

10. Global Peptide Cancer Vaccine Clinical Trials Insight
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-III

11. LucaVax – First Commercially available Peptide Cancer Vaccine

12. Global Peptide Cancer Vaccine Market Dynamics
12.1 Market Driving Factors
12.2 Challenges Ahead For Peptide Cancer Vaccine Market Development

13. Peptide Cancer Vaccine: Promising Candidate of Cancer Immunotherapy
14. Competitive Landscape
14.1 Enzo Life Science (Alexis Biotech)
14.2 Antigen Express
14.3 BioLife Science
14.4 Immatics Biotechnologies
14.5 Immune Design
14.6 Imugene
14.7 Immunomedics
14.8 ISA Pharmaceuticals
14.9 Galena Biopharma
14.10 Generex Biotechnology Corporation
14.11 Lytix Biopharma
14.12 Merck (Merck Serono)
14.13 OncoTherapy Science
14.14 Oncothyreon
14.15 Pfizer
14.16 Phylogica
14.17 Symphogen (Receptor BioLogix)
14.18 Sumitomo Dainippon Pharma
14.19 TapImmune
14.20 Vaxon Biotech

List of Figures
Figure 1-1: Advantages of Peptide Cancer Vaccines

Figure 2-1: Peptides - Amino Acid & Proteins
Figure 2-2: Diversification of Vaccines
Figure 2-3: Sub-Unit Vaccines V/S Traditional Vaccines

Figure 3-1: Classification of Peptide Vaccine by Source
Figure 3-2: Classification on Basis of Length
Figure 3-3: On the Basis of Epitopes

Figure 4-1: Immunological Cells Activated By Peptide Cancer Vaccines
Figure 4-2: Procedure of Synthetic Peptide Cancer Vaccine Development
Figure 4-3: Determination of Antigen Components, Its Selection & Construction
Figure 4-4: Role of Adjuvants in Peptide Cancer Vaccines
Figure 4-5: Investigation of Efficiency & Immune Response to Synthetic Peptide Cancer Vaccine

Figure 5-1: Clinical Trial Study of WT1 Peptide Vaccine for Acute Myeloid Leukemia Patients
Figure 5-2: WT1 Peptide as a Marker for Cancer Therapy
Figure 5-3: Methodologies Involved In the Clinical Study

Figure 6-1: Peptides & Colorectal Cancer
Figure 6-2: Peptides & Lung Cancer
Figure 6-3: Peptides & Pancreatic Cancer
Figure 6-4: Peptides & Gastric Cancer
Figure 6-5: Peptides & Prostate Cancer
Figure 6-6: Peptides & Breast Cancer


Figure 7-1: Global – Peptide Therapeutic Market Size (US$ Billion), 2018 - 2026
Figure 7-2: Global – Total Peptide Therapeutic Market Size vs. Oncological Peptide Therapeutic Market Size (US$ Billion), 20120
Figure 7-3: Global – Oncological Peptide Therapeutics Market Share in Total Peptide market (%), 2020
Figure 7-4: Global – Peptide Oncology Drugs Market Size (US$ Billion), 2018 - 2026
Figure 7-5: Peptide Oncology Market – Regional Market Share (%), 2019

Figure 8-1: Optimized Cryptic Peptides
Figure 8-2: Therapeutic CpG Peptide-Based Cancer Vaccine
Figure 8-3: Personalized Neoantigen Vaccination with Synthetic Long Peptides
Figure 8-4: Recombinant Peptide Vaccine
Figure 8-5: p53 Peptide-Pulsed Dendritic Cells Cancer Vaccine

Figure 9-1: Global - Peptide Cancer Vaccine in Clinical Pipeline by Country, 2021 till 2026
Figure 9-2: Global - Peptide Cancer Vaccine in Clinical Pipeline by Company, 2021 till 2026
Figure 9-3: Global - Peptide Cancer Vaccine in Clinical Pipeline by Patient Segment, 2021 till 2026
Figure 9-4: Global - Peptide Cancer Vaccine in Clinical Pipeline by Phase, 2021 till 2026

Figure 12-1: Market Drivers of Peptide Cancer Vaccines
Figure 12-2: Peptide Cancer Vaccine: An Active Immunotherapy
Figure 12-3: Peptide Cancer Vaccine: A Personalized, Targeted Therapy
Figure 12-4: Peptide Cancer Vaccine: Highly Efficient, High Immunogenic Response Generating
Figure 12-5: Peptide Cancer Vaccine: Multiple Tumors Targeting Ability
Figure 12-6: Peptide Cancer Vaccine: A Viable Solution to Immunotolerance
Figure 12-7: Peptide Cancer Vaccine: Improves the Quality Of Life & is Cost Effective
Figure 12-8: Challenges of Peptide Cancer Vaccine: The Parameters Related To the Clinical Trials
Figure 12-9: Single Antigen Based Peptide Vaccine: Highly Prone To Failure
Figure 12-10: Lack of Standardized Parameters for Assessing the Result of Clinical Trials
Figure 12-11: Variable Therapeutic Window for Different Patients
Figure 12-12: Cancer Immunoediting: The Three Es; Tumor Elimination, Equilibrium & Escape

Figure 14-1: Enzo Life Science Pipeline
Figure 14-2: Immatics Biotechnologies Pipeline
Figure 14-3: Immune Design Pipeline
Figure 14-4: Imugene Pipeline
Figure 14-5: ISA Pharmaceuticals Pipeline
Figure 14-6: Galena Biopharma Pipeline
Figure 14-7: Generex Biotechnology Pipeline
Figure 14-8: Lytix Biopharma Pipeline
Figure 14-9: Merck Clinical Pipeline
Figure 14-10: Onco Therapy Science Pipeline
Figure 14-11: Oncothyreon Pipeline
Figure 14-12: Sumitomo Dainippon Pharma Pipeline
Figure 14-13: Tapimmune Pipeline
Figure 14-14: Vaxon Biotech Pipeline